

2019, Allgemeine Pathologie Heidelberg

Rot: Erst/Letztautorenschaft

**geteilte Erst- oder Letztautorenschaft*

1. Albrecht T, Goepfert B. Hyperplastic Polyp With an Unexpected Finding. *Int J Surg Pathol*. 2019 May;27(3):275-276. (IF: 0.98)
2. Albrecht T, Harms A, Roessler S, Goepfert B. NUT carcinoma in a nutshell: A diagnosis to be considered more frequently. *Pathol Res Pract*. 2019 Jun;215(6):152347. (IF: 1.80)
3. Albrecht T, Mehrabi A, Strobel O, Vogel MN, Stenzinger A, Bergmann F, Schirmacher P, Goepfert B. Undifferenziertes Karzinom des distalen Gallengangs vom Spindel und Riesenzelltyp: Ein Fallbericht. *Z Gastroenterol*. 2019 Jan;57(1):52-56. (IF: 1.24)
4. Albrecht T, Rausch M, Rössler S, Albrecht M, Braun JD, Geissler V, Mehrabi A, Vogel MN, Pathil-Warth A, Mechtersheimer G, Renner M, Rupp C, Weiss KH, Busch E, Köhler B, Springfield C, Schirmacher P, Goepfert B. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. *BMC Cancer*. 2019 Dec 5;19(1):1191. (IF: 2.93)
5. Alwers E, Bläker H, Walter V, Jansen L, Kloor M, Arnold A, Sieber-Frank J, Herpel E, Tagscherer KE, Roth W, Chang-Claude J, Brenner H, Hoffmeister M. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. *BMC Cancer*. 2019 Jul 11;19(1):681. (IF: 2.93)
6. Amitay EL, Carr PR, Jansen L, Walter V, Roth W, Herpel E, Kloor M, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M. Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. *J Natl Cancer Inst*. 2019 May 1;111(5):475-483. (IF: 10.21)
7. Andres A, Zeier M, Eckert C. Acute Kidney Injury Following High-Dose Vitamin C Treatment. *Dtsch Arztebl Int*. 2019 Nov 1;116(44):756. (IF: 3.90)
8. Baber R, Hummel M, Jahns R, von Jagwitz-Biegnitz M, Kirsten R, Klingler C, Nussbeck SY, Specht C. Position Statement from the German Biobank Alliance on the Cooperation Between Academic Biobanks and Industry Partners. *Biopreservation and Biobanking*. 2019 Aug;17(4):372-374. (IF: 1.362)
9. Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyle B, Poth T, Jäger D, Ungerechts G, Engeland CE. Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists. *Viruses*. 2019 Oct 3;11(10): 1-21. (IF: 3.81)
10. Badr M, Jöhrens K, Allgäuer M, Boxberg M, Weichert W, Tinhofer I, Denkert C, Schirmacher P, Stenzinger A, Budczies J. Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. *Cancer Immunol Immunother*. 2019 Sep;68(9):1443-1454. (IF: 4.90)
11. Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS. Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤ 2 cm) Lung Adenocarcinoma: An International Cohort Analysis. *J Thorac Oncol*. 2019 Jan;14(1):72-86. (IF: 12.46)

12. Ballin N, Hotz A, Bourrat E, Küsel J, Oji V, Bouadjar B, Brognoli D, Hickman G, Heinz L, Vabres P, Marrakchi S, Leclerc-Mercier S, Irvine A, Tadini G, Hamm H, Has C, Blume-Peytavi U, Mitter D, Reitenbach M, Hausser I, Zimmer AD, Alter S, Fischer J. Genetical, clinical, and functional analysis of a large international cohort of patients with autosomal recessive congenital ichthyosis due to mutations in NIPAL4. *Hum Mutat.* 2019 Dec;40(12):2318-2333. (IF: 4.45)
13. Baretton G, Kreipe HH, Schirmacher P, Gaiser T, Hofheinz R, Berghäuser KH, Koch W, Künzel C, Morris S, Rüschoff J. Nicht-interventionelle Untersuchung (NIU) HER2 Study Group. HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany. *Virchows Arch.* 2019 May;474(5):551-560. (IF: 2.87)
14. Bartosova M, Schaefer B, Vondrak K, Sallay P, Taylan C, Cerkauskiene R, Dzierzega M, Milosevski-Lomic G, Büscher R, Zaloszyc A, Romero P, Lasitschka F, Warady BA, Schaefer F, Ujszaszi A, Schmitt CP. Peritoneal Dialysis Vintage and Glucose Exposure but Not Peritonitis Episodes Drive Peritoneal Membrane Transformation During the First Years of PD. *Front Physiol.* 2019 Apr 2;10:356. (IF: 3.20)
15. Bläker H, Alwers E, Arnold A, Herpel E, Tagscherer KE, Roth W, Jansen L, Walter V, Kloor M, Chang-Claude J, Brenner H, Hoffmeister M. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. *Clin Gastroenterol Hepatol.* 2019 Feb;17(3):455-462.e6. (IF: 7.96)
16. Bochtler T*, Endris V*, Leichsenring J, Reiling A, Neumann O, Volckmar AL, Kirchner M, Allgäuer M, Schirmacher P, Krämer A, Stenzinger A. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. *Int J Cancer.* 2019 Dec 1;145(11):2963-2973. (IF: 4.98)
17. Bonafont J, Mencía Á, García M, Torres R, Rodríguez S, Carretero M, Chacón-Solano E, Modamio-Høybjør S, Marinas L, León C, Escamez MJ, Hausser I, Del Río M, Murillas R, Larcher F. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing. *Mol Ther.* 2019 May 8;27(5):986-998. (IF: 8.40)
18. Bonekamp D, Schelb P, Wiesenfarth M, Kuder TA, Deister F, Stenzinger A, Nyarangi-Dix J, Röthke M, Hohenfellner M, Schlemmer HP, Radtke JP. Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. *Eur Radiol.* 2019 Apr;29(4):1820-1830. (IF: 3.96)
19. Boxberg M, Kuhn PH, Reiser M, Erb A, Steiger K, Pickhard A, Straßen U, Koob I, Kolk A, Warth A, Jesinghaus M, Weichert W. Tumor Budding and Cell Nest Size Are Highly Prognostic in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: Further Evidence for a Unified Histopathologic Grading System for Squamous Cell Carcinomas of the Upper Aerodigestive Tract. *Am J Surg Pathol.* 2019 Mar;43(3):303-313. (IF: 6.16)
20. Bozorgmehr F, Hommertgen A, Krisam J, Lasitschka F, Kuon J, Maenz M, Huber PE, König L, Kieser M, Debus J, Thomas M, Rieken S. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. *BMC Cancer.* 2019 Nov 8;19(1):1074. (IF: 2.93)
21. Braconi C, Roessler S, Kruk B, Lammert F, Krawczyk M, Andersen JB. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine? *Liver Int.* 2019 May;39 Suppl 1:32-42. (IF: 5.54)
22. Breinig M, Schweitzer AY, Herianto AM, Revia S, Schaefer L, Wendler L, Cobos Galvez A, Tschaharganeh DF. Multiplexed orthogonal genome editing and transcriptional activation by Cas12a. *Nat Methods.* 2019 Jan;16(1):51-54. (IF: 28.46)

23. Brix SR, Huber TB, Waldherr R, Hopfer H, Stahl RAK, Wiech T. The authors reply. *Kidney Int.* 2019 Jul;96(1):245-246. (IF: 8.31)
24. Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. *Int J Cancer.* 2019 Feb 15;144(4):848-858. (IF: 4.98)
25. Buck E, Sprick M, Gaida MM, Grüllich C, Weber TF, Herpel E, Bruckner T, Koschny R. Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. *Oncol Lett.* 2019 Apr;17(4):3890-3898. (IF: 1.87)
26. Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A. Optimizing panel-based tumor mutational burden (TMB) measurement. *Ann Oncol.* 2019 Sep 1;30(9):1496-1506. (IF: 14.20)
27. Casadonte R*, Kriegsmann M*, Perren A, Baretton G, Deininger SO, Kriegsmann K, Welsch T, Pilarsky C, Kriegsmann J. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800046. (IF: 2.32)
28. Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol.* 2019 Jan 1;30(1):44-56. (IF: 14.20)
29. Christopoulos P*, Dietz S*, Kirchner M*, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sülthmann H, Stenzinger A. Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. *Cancers (Basel).* 2019 Jan 21;11(1). pii: E124. (IF: 6.16)
30. Christopoulos P, Budczies J, Kirchner M, Dietz S, Sülthmann H, Thomas M, Stenzinger A. Defining molecular risk in ALK+ NSCLC. *Oncotarget.* 2019 May 3;10(33):3093-3103. (IF: 5.17)
31. Christopoulos P*, Kirchner M*, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A. Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma. *Int J Cancer.* 2019 Jan 1;144(1):190-199. (IF: 4.98)
32. Cordero Hernandez Y, Boskamp T, Casadonte R, Hauberg-Lotte L, Oetjen J, Lachmund D, Peter A, Trede D, Kriegsmann K, Kriegsmann M, Kriegsmann J, Maass P. Targeted Feature Extraction in MALDI Mass Spectrometry Imaging to Discriminate Proteomic Profiles of Breast and Ovarian Cancer. *Proteomics Clin Appl.* 2019 Jan;13(1):e1700168. (IF: 2.32)
33. Delecluse S, Tsai MH, Shumilov A, Bencun M, Arrow S, Beshirova A, Cottignies-Calamarte A, Lasitschka F, Bulut OC, Münz C, Zeier M, Behrends U, Delecluse HJ. Epstein-Barr Virus Induces Expression of the LPAM-1 Integrin in B Cells In Vitro and In Vivo. *J Virol.* 2019 Feb 19;93(5). pii: e01618-18. (IF: 4.32)
34. Denkert C*, Budczies J*, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. *Breast Cancer Res Treat.* 2019 Aug;176(3):557-568. (IF: 3.47)
35. Dietz S, Christopoulos P, Gu L, Volckmar AL, Endris V, Yuan Z, Ogrodnik SJ, Zemojtel T, Heussel CP, Schneider MA, Meister M, Muley T, Reck M, Schlesner M, Thomas M, Stenzinger A, Sülthmann

- H. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancer. *Cold Spring Harb Mol Case Stud.* 2019 Dec 13;5(6). pii: a004630. (IF: 1.75)
36. Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H. Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. *Int J Cancer.* 2019 Mar 1;144(5):1061-1072. (IF: 4.98)
37. Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. *Breast Care (Basel).* 2019 Aug;14(4):224-245. (IF: 2.09)
38. Drucker E, Holzer K, Pusch S, Winkler J, Calvisi DF, Eiteneuer E, Herpel E, Goeppert B, Roessler S, Ori A, Schirmacher P, Breuhahn K, Singer S. Karyopherin $\alpha 2$ -dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. *Cell Commun Signal.* 2019 Nov 29;17(1):1-14. (IF: 5.11)
39. Ehrenberg KR, Gao J, Oppel F, Frank S, Kang N, Dieter SM, Herbst F, Möhrmann L, Dubash TD, Schulz ER, Strakerjahn H, Giessler KM, Weber S, Oberlack A, Rief EM, Strobel O, Bergmann F, Lasitschka F, Weitz J, Glimm H, Ball CR. Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. *Cells.* 2019 Feb 10;8(2). pii: E142. (IF: 5.66)
40. Eichhorn F, Klotz LV, Bischoff H, Thomas M, Lasitschka F, Winter H, Hoffmann H, Eichhorn ME. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. *BMC Cancer.* 2019 May 2;19(1):413. (IF: 2.93)
41. Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC. Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. *Gastroenterology.* 2019 Mar;156(4):1190-1205.e14. (IF: 19.23)
42. Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. *Int J Cancer.* 2019 May 1;144(9):2303-2312. (IF: 4.98)
43. Ercetin E, Richtmann S, Delgado BM, Gomez-Mariano G, Wrenger S, Korenbaum E, Liu B, DeLuca D, Kühnel MP, Jonigk D, Yuskaeva K, Warth A, Muley T, Winter H, Meister M, Welte T, Janciauskiene S, Schneider MA. Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC. *Cancers (Basel).* 2019 Sep 4;11(9). (IF: 6.16)
44. Erlangga Z, Wolff K, Poth T, Peltzer A, Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP, Saborowski A, Vogel A, Saborowski M. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. *Cancers (Basel).* 2019 Nov 29;11(12): E1904. (IF: 6.16)
45. Fahim Golestaneh A, Lecker LSM, Schlegel J, Nowrouzi A, Schwager C, Meister S, Weichert W, Debus J, Abdollahi A. Large scale in vivo micro-RNA loss of function screen identified miR-29a,

- miR-100 and miR-155 as modulators of radioresistance and tumor-stroma communication. *Int J Cancer*. 2019 Jun 1;144(11):2774-2781. (IF: 4.98)
46. Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, Fu Y, Li N, He Y, Liu C, Zhang Y, Lian Q, Zhao X, Yan C, Li L, Yi C, Ling Z, Ma L, Zhao X, Xu H, Wang P, Cong M, You H, Liu Z, Wang Y, Chen J, Li D, Hui L, Dooley S, Hou J, Jia J, Sun B. ECM1 Prevents Activation of Transforming Growth Factor β , Hepatic Stellate Cells, and Fibrogenesis in Mice. *Gastroenterology*. 2019 Nov;157(5):1352-1367.e13. (IF: 19.23)
 47. Ferré EMN, Break TJ, Burbelo PD, Allgäuer M, Kleiner DE, Jin D, Xu Z, Folio LR, Mollura DJ, Swamydas M, Gu W, Hunsberger S, Lee CR, Bondici A, Hoffman KW, Lim JK, Dobbs K, Niemela JE, Fleisher TA, Hsu AP, Snow LN, Darnell DN, Ojaimi S, Cooper MA, Bozzola M, Kleiner GI, Martinez JC, Deterding RR, Kuhns DB, Heller T, Winer KK, Rajan A, Holland SM, Notarangelo LD, Fennelly KP, Olivier KN, Lionakis MS. Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. *Sci Transl Med*. 2019 Jun 5;11(495). pii: eaav5597. (IF: 17.16)
 48. Fischer S, Federspil PA, Kriegsmann K, Longerich T, Kriegsmann M. Concurrent Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma) and Squamous Cell Carcinoma of the Skin on the Right Ear Helix. *Int J Surg Pathol*. 2019 Feb;27(1):64-66. (IF: 0.98)
 49. Fischer-Zirnsak B, Koenig R, Alisch F, Güneş N, Hausser I, Saha N, Beck-Woedl S, Haack TB, Thiel C, Kamrath C, Tüysüz B, Henning S, Mundlos S, Hoffmann K, Horn D, Kornak U. SOPH syndrome in three affected individuals showing similarities with progeroid cutis laxa conditions in early infancy. *J Hum Genet*. 2019 Jul;64(7):609-616. (IF: 3.55)
 50. Fonouni H, Khajeh E, Ghamarnejad O, Kashfi A, Aydogdu E, Majlesara A, Mohammadi S, Gharabaghi N, Konstantinidis L, Longerich T, Mehrabi A, Kulu Y. Histopathological effects of modern topical sealants on the liver surface after hepatectomy: an experimental swine study. *Sci Rep*. 2019 May 8;9(1):7088. (IF: 4.01)
 51. Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. *Clin Chem*. 2019 Apr;65(4):549-558. (IF: 6.89)
 52. Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A. Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. *Breast Care (Basel)*. 2019 Mar;14(1):53-59. (IF: 2.09)
 53. Fricke F, Michalak M, Warnken U, Hausser I, Schnölzer M, Kopitz J, Gebert J. SILAC-Based Quantification of TGFBR2-Regulated Protein Expression in Extracellular Vesicles of Microsatellite Unstable Colorectal Cancers. *Int J Mol Sci*. 2019 Aug 26;20(17). pii: E4162. (IF: 4.18)
 54. Fricke F, Mussack V, Buschmann D, Hausser I, Pfaffl MW, Kopitz J, Gebert J. TGFBR2-dependent alterations of microRNA profiles in extracellular vesicles and parental colorectal cancer cells. *Int J Oncol*. 2019 Oct;55(4):925-937. (IF: 3.57)
 55. Froehlich TC, Müller-Decker K, Braun JD, Albrecht T, Schroeder A, Gülow K, Goerdts S, Krammer PH, Nicolay JP. Combined inhibition of Bcl-2 and NF κ B synergistically induces cell death in cutaneous T-cell lymphoma. *Blood*. 2019 Aug 1;134(5):445-455. (IF: 16.56)
 56. Giusca S, Buss S, Lasitschka F, Karck M, Korosoglou G. Syncope in a female patient. Echocardiography and cardiac computed tomography reveal an unexpected diagnosis. *Clin Case Rep*. 2019 May 7;7(6):1167-1170. (IF: unkn.)

57. Glaeser A, Sinn HP, Garcia-Etienne C, Riedel F, Hug S, Schaeffgen B, Golatta M, Hennigs A, Feisst M, Sohn C, Heil J. Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype. *Ann Surg Oncol*. 2019 Dec;26(13):4381-4389. (IF: 3.68)
58. Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. *Hepatology*. 2019 May;69(5):2091-2106. (IF: 14.97)
59. Goeppert B, Truckenmueller F, Ori A, Fritz V, Albrecht T, Fraas A, Scherer D, Silos RG, Sticht C, Gretz N, Mehrabi A, Bewerunge-Hudler M, Pusch S, Bermejo JL, Dietrich P, Schirmacher P, Renner M, Roessler S. Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. *Sci Rep*. 2019 Mar 18;9(1):4796. (IF: 4.01)
60. Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfield C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. *Sci Rep*. 2019 Mar 13;9(1):4338. (IF: 4.01)
61. Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfield C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. *Br J Cancer*. 2019 Jan;120(1):109-114. (IF: 5.42)
62. Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfield C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M. Low frequency of mismatch repair deficiency in gallbladder cancer. *Diagn Pathol*. 2019 May 8;14(1):36. (IF: 2.53)
63. Groener JB, Gelen D, Mogler C, Herpel E, Toth C, Kender Z, Peichl M, Haufe S, Haberkorn U, Sulaj A, Zemva J, Kopf S, Nawroth PP, Brune M, Rudofsky G. BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer. *Horm Metab Res*. 2019 Jan;51(1):69-75. (IF: 2.42)
64. Gröschel S, Hübschmann D, Raimondi F, Horak P, Warsow G, Fröhlich M, Klink B, Geldon L, Hutter B, Kleinheinz K, Bonekamp D, Marschal O, Chudasama P, Mika J, Groth M, Uhrig S, Krämer S, Heining C, Heilig CE, Richter D, Reisinger E, Pfütze K, Eils R, Wolf S, von Kalle C, Brandts C, Scholl C, Weichert W, Richter S, Bauer S, Penzel R, Schröck E, Stenzinger A, Schlenk RF, Brors B, Russell RB, Glimm H, Schlesner M, Fröhling S. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. *Nat Commun*. 2019 Apr 9;10(1):1635. (IF: 11.88)
65. Gündert M, Edelmann D, Benner A, Jansen L, Jia M, Walter V, Knebel P, Herpel E, Chang-Claude J, Hoffmeister M, Brenner H, Burwinkel B. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). *Gut*. 2019 Jan;68(1):101-110. (IF: 17.94)
66. Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfield C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. *Int J Cancer*. 2019 Apr 1;144(7):1697-1703. (IF: 4.98)
67. Haffa M, Holowatyj AN, Kratz M, Toth R, Benner A, Gigic B, Habermann N, Schrotz-King P, Böhm J, Brenner H, Schneider M, Ulrich A, Herpel E, Schirmacher P, Straub BK, Nattenmüller J, Kauczor HU, Lin T, Ball CR, Ulrich CM, Glimm H, Scherer D. Transcriptome Profiling of Adipose Tissue

- Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. *J Clin Endocrinol Metab.* 2019 Nov 1;104(11):5225-5237. (IF: 5.61)
68. Hafner A, Kolbe U, Freund I, Castiglia V, Kovarik P, Poth T, Herster F, Weigand MA, Weber ANR, Dalpke AH, Eigenbrod T. Crucial Role of Nucleic Acid Sensing via Endosomal Toll-Like Receptors for the Defense of *Streptococcus pyogenes* in vitro and in vivo. *Front Immunol.* 2019 Feb 21;10:198. (IF: 4.78)
69. Hakimi M, Wortmann M, Böckler D, Schirmacher P, Herpel E, Peters AS. Vascular Biomaterial Banking in Academia. *Eur Surg Res.* 2019;60(1-2):13-23. (IF: 1.63)
70. Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C. BRAF mutation testing in melanoma: results from a German observational multicenter study. *Virchows Arch.* 2019 Jan;474(1):71-78. (IF: 2.87)
71. Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. *Cancers (Basel).* 2019 Aug 29;11(9). pii: E1271. (IF: 6.16)
72. Hippchen T, Sauer P, Göppert B, Schirmacher P, Gotthardt DN, Weiss KH, Stremmel W, Rupp C. Association between serum IgG level and clinical course in primary sclerosing cholangitis. *BMC Gastroenterol.* 2019 Aug 27;19(1):153. (IF: 2.25)
73. Högerle BA, Lasitschka F, Muley T, Bougatf N, Herfarth K, Adeberg S, Eichhorn M, Debus J, Winter H, Rieken S, Uhl M. Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institution. *Radiat Oncol.* 2019 Jul 4;14(1):117. (IF: 5.25)
74. Höppener DJ, Nierop PMH, Herpel E, Rahbari NN, Doukas M, Vermeulen PB, Grünhagen DJ, Verhoef C. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy. *Clin Exp Metastasis.* 2019 Aug;36(4):311-319. (IF: 2.51)
75. Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio AL, Mackmull MT, Baßler J, Roessler S, Breuhahn K, Zender L, Glavy JS, Dombrowski F, Hurt E, Schirmacher P, Beck M, Singer S. Nucleoporin Nup155 is part of the p53 network in liver cancer. *Nat Commun.* 2019 May 14;10(1):2147. (IF: 11.88)
76. Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T. Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. *Cold Spring Harb Mol Case Stud.* 2019 Apr 1;5(2). pii: a003657. (IF: 1.75)
77. Hou Y, Pinheiro J, Sahm F, Reuss DE, Schrimpf D, Stichel D, Casalini B, Koelsche C, Sievers P, Wefers AK, Reinhardt A, Ebrahimi A, Fernández-Klett F, Pusch S, Meier J, Schweizer L, Paulus W, Prinz M, Hartmann C, Plate KH, Reifenberger G, Pietsch T, Varlet P, Pagès M, Schüller U, Scheie D, de Stricker K, Frank S, Hench J, Pollo B, Brandner S, Unterberg A, Pfister SM, Jones DTW, Korshunov A, Wick W, Capper D, Blümcke I, von Deimling A, Bertero L. Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathol.* 2019 May;137(5):837-846. (IF: 18.17)
78. Hruban RH, Gaida MM, Thompson E, Hong SM, Noë M, Brosens LA, Jongepier M, Offerhaus GJA, Wood LD. Why is pancreatic cancer so deadly? The pathologist's view. *J Pathol.* 2019 Jun;248(2):131-141. (IF: 5.94)

79. Hummel M, Specht C, Herpel E, Huth V. Modern Biobanks Part 1: An Indispensable Resource in Biomedical Research. *G.I.T. Laboratory Journal*. 2019 Feb; 18–19. (IF: unkn.)
80. Isfort I, Elges S, Cyra M, Berthold R, Renner M, Mechtersheimer G, Åman P, Larsson O, Ratner N, Hafner S, Simmet T, Schliemann C, Rossig C, Dirksen U, Grünewald I, Wardelmann E, Huss S, Hartmann W, Trautmann M. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. *Sci Rep*. 2019 Dec 23;9(1):19704. (IF: 4.01)
81. Itzel T, Spang R, Maass T, Munker S, Roessler S, Ebert MP, Schlitt HJ, Herr W, Evert M, Teufel A. Random gene sets in predicting survival of patients with hepatocellular carcinoma. *J Mol Med (Berl)*. 2019 Jun;97(6):879-888. (IF: 4.75)
82. Jansen PLM, Breuhahn K, Teufel A, Dooley S. Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology. *Front Physiol*. 2019 Nov 22;10:1438. (IF: 3.20)
83. Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. *Breast Cancer Res Treat*. 2019 Jan;173(1):155-165. (IF: 3.47)
84. Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. *Cancer Immunol Immunother*. 2019 Oct;68(10):1621-1633. (IF: 4.90)
85. Jesinghaus M, Boxberg M, Wilhelm D, Münch S, Dapper H, Quante M, Schlag C, Lange S, Budczies J, Konukiewicz B, Mollenhauer M, Schlitter AM, Becker KF, Feith M, Friess H, Steiger K, Combs SE, Weichert W. Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. *Br J Cancer*. 2019 Dec;121(12):1050-1057. (IF: 5.42)
86. Jia M, Zhang Y, Jansen L, Walter V, Edelmann D, Gündert M, Tagscherer KE, Roth W, Bewerunge-Hudler M, Herpel E, Kloor M, Ulrich A, Burwinkel B, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival. *Clin Epigenetics*. 2019 Jul 24;11(1):109. (IF: 5.50)
87. Jour G, Serrano J, Koelsche C, Jones DTW, von Deimling A, Allen J, Snuderl M. Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. *J Neuropathol Exp Neurol*. 2019 Nov 1;78(11):1073-1075. (IF: 3.46)
88. Kather JN, Krisam J, Charoentong P, Luedde T, Herpel E, Weis CA, Gaiser T, Marx A, Valous NA, Ferber D, Jansen L, Reyes-Aldasoro CC, Zörnig I, Jäger D, Brenner H, Chang-Claude J, Hoffmeister M, Halama N. Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study. *PLoS Med*. 2019 Jan 24;16(1):e1002730. (IF: 11.05)
89. Kather JN, Heij LR, Grabsch HI, Kooreman LFS, Loeffler C, Echle A, Krause J, Muti HS, Niehues JM, Sommer KAJ, Bankhead P, Schulte JJ, Cipriani NA, Ortiz-Brüchle N, Patnaik A, Srisuwananukorn A, Brenner H, Hoffmeister M, van den Brandt PA, Jäger D, Trautwein C, Pearson AT, Luedde T. Pan-cancer image-based detection of clinically actionable genetic alterations. *Cold Spring Harbour Laboratory*. 2019 Nov: 1-19. (IF: unkn.)
90. Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M. Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of

- Activating Mutations in Pulmonary Adenocarcinoma. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800034. (IF: 2.32)
91. Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. *J Thorac Oncol.* 2019 Nov;14(11):1935-1947. (IF: 12.46)
 92. Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. *Liver Int.* 2019 May;39 Suppl 1:7-18. (IF: 5.54)
 93. Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeke E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R. Lungscape Consortium. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. *Lung Cancer.* 2019 May;131:95-103. (IF: 4.60)
 94. Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfield C, Schirmacher P, Penzel R, Endris V, Stenzinger A. RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. *Cancers (Basel).* 2019 Sep 5;11(9). pii: E1309. (IF: 6.16)
 95. Klupp F, Klauss M, Rahbari NN, Felix K, Hinz U, Manglberger I, Bergmann F, Gaida MM, Hackert T, Strobel O, Büchler MW. Volume changes of the pancreatic head remnant after distal pancreatectomy. *Surgery.* 2019 Oct 17. pii: S0039-6060(19)30663-4. (IF: 3.48)
 96. Klupp F, Giese C, Halama N, Franz C, Lasitschka F, Warth A, Schmidt T, Kloor M, Ulrich A, Schneider M. E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer. *Cancer Manag Res.* 2019 Feb 22;11:1795-1803. (IF: 2.24)
 97. Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. *J Viral Hepat.* 2019 Feb;26(2):224-230. (IF: 4.02)
 98. Koelsche C, Kriegsmann M, Kommos FKF, Stichel D, Kriegsmann K, Vokuhl C, Grünewald TGP, Romero-Pérez L, Kirchner T, de Alava E, Diaz-Martin J, Hartmann W, Baumhoer D, Antonescu CR, Szuhai K, Flucke U, Dirksen U, Pfister SM, Jones DTW, Mechttersheimer G, von Deimling A. DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. *J Cancer Res Clin Oncol.* 2019 May;145(5):1273-1281. (IF: 3.33)
 99. Koelsche C, Stichel D, Griewank KG, Schimpf D, Reuss DE, Bewerunge-Hudler M, Vokuhl C, Dinjens WNM, Petersen I, Mittelbronn M, Cuevas-Bourdier A, Buslei R, Pfister SM, Flucke U, Mechttersheimer G, Mentzel T, von Deimling A. Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. *Clin Sarcoma Res.* 2019 Feb 14;9:2. (IF: unkn.)

100. Kohlruss M, Grosser B, Krenauer M, Slotta-Huspenina J, Jesinghaus M, Blank S, Novotny A, Reiche M, Schmidt T, Ismani L, Hapfelmeier A, Mathias D, Meyer P, Gaida MM, Bauer L, Ott K, Weichert W, Keller G. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability. *J Pathol Clin Res.* 2019 Oct;5(4):227-239. (IF: unkn.)
101. Kommos F, Ebel T, Drusenheimer J, Schelzig H, Lichtenberg A, Fehm T, Aubin H. Die intravenöse Leiomyomatose. *Pathologe.* 2019 Feb;40(1):80-84. (IF: 0.55)
102. Korkmaz-Icöz S, Li S, Hüttner R, Ruppert M, Radovits T, Loganathan S, Sayour AA, Brlecic P, Lasitschka F, Karck M, Szabó G. Hypothermic perfusion of donor heart with a preservation solution supplemented by mesenchymal stem cells. *J Heart Lung Transplant.* 2019 Mar;38(3):315-326. (IF: 8.58)
103. Koschny R, Allgäuer M, Pfeiffenberger J, Seessle J, Fuchs J, Longerich T, Wielpütz MO, Hoffmann K. Case report: a rare cause of a hypervascular nodule in a noncirrhotic liver. *Z Gastroenterol.* 2019 Jan;57(1):57-60. (IF: 1.24)
104. Krämer A, Stenzinger A. Karzinome mit unklarer Primärlokalisation – CheCUP-Studie. *Forum. Sektion B – Klinische Studien.* 2019 Oct 4;34:559-560. (IF: unkn.)
105. Kriegsmann J, Kriegsmann M, Kriegsmann K, Longuespée R, Deininger SO, Casadonte R. MALDI Imaging for Proteomic Painting of Heterogeneous Tissue Structures. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800045. (IF: 2.32)
106. Kriegsmann K, Cremer M, Zgorzelski C, Harms A, Muley T, Winter H, Kazdal D, Warth A, Kriegsmann M. Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer. *Pathology.* 2019 Apr;51(3):240-245, (IF: 3.16)
107. Kriegsmann K, Longuespée R, Hundemer M, Zgorzelski C, Casadonte R, Schwamborn K, Weichert W, Schirmacher P, Harms A, Kazdal D, Leichsenring J, Stenzinger A, Warth A, Fresnais M, Kriegsmann J, Kriegsmann M. Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800035. (IF: 2.32)
108. Kriegsmann K, Klee JS, Hensel M, Buss EC, Kriegsmann M, Cremer M, Ho AD, Egerer G, Wuchter P, Witzens-Harig M. Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis. *Clin Lymphoma Myeloma Leuk.* 2019 Oct;19(10):e581-e587. (IF: 2.27)
109. Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M. Cell-based immunotherapy approaches for multiple myeloma. *Br J Cancer.* 2019 Jan;120(1):38-44. (IF: 5.42)
110. Kriegsmann K, Wack M, Pavel P, Schmitt A, Kriegsmann M, Bruckner T, Müller-Tidow C, Wuchter P. Collection, Cryostorage, Transplantation, and Disposal of Hematopoietic Stem Cell Products. *Biol Blood Marrow Transplant.* 2019 Feb;25(2):382-390. (IF: 3.60)
111. Kriegsmann M, Roessler S, Kriegsmann K, Renner M, Longuespée R, Albrecht T, Loeffler M, Singer S, Mehrabi A, Vogel MN, Pathil A, Köhler B, Springfield C, Rupp C, Weiss KH, Goepfert B. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. *BMC Cancer.* 2019 Jan 15;19(1):72. (IF: 2.93)
112. Kriegsmann M, Gomez C, Heil J, Schäffgen B, Gutjahr E, Kommos FKF, Kriegsmann K, Flechtenmacher C, Goepfert B, Sinn HP. IgG4-related sclerosing mastitis in a 49-year-old patient with multiple, tumor-like nodules-Diagnostic accuracy of core needle biopsy. *Breast J.* 2019 Nov;25(6):1251-1253. (IF: 3.49)

113. Krishna-Subramanian S, Singer S, Armaka M, Banales JM, Holzer K, Schirmacher P, Walczak H, Kollias G, Pasparakis M, Kondylis V. RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. *Cell Death Differ.* 2019 Dec;26(12):2710-2726. (IF: 8.09)
114. Lebeau A, Denkert C, Sinn P, Schmidt M, Wöckel A. Update of the German S3 breast cancer guideline: What is new for pathologists? *Pathologe.* 2019 Mar;40(2):185-198. (IF: 0.55)
115. Lee JC, Villanueva-Meyer JE, Ferris SP, Sloan EA, Hofmann JW, Hattab EM, Williams BJ, Guo H, Torkildson J, Florez A, Van Ziffle J, Onodera C, Grenert JP, Cho SJ, Horvai AE, Jones DTW, Pfister SM, Koelsche C, von Deimling A, Korshunov A, Perry A, Solomon DA. Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathol.* 2019 Mar;137(3):521-525. (IF: 18.17)
116. Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A. Variant classification in precision oncology. *Int J Cancer.* 2019 Dec 1;145(11):2996-3010. (IF: 4.98)
117. Leichsenring J, Kazdal D, Ploeger C, Allgäuer M, Endris V, Volckmar AL, Neumann O, Kirchner M, Penzel R, Rempel E, Budczies J, Schirmacher P, Fröhling S, Stenzinger A. Von der Paneldiagnostik zu umfassenden genomischen Analysen Informationsüberfluss oder Zugewinn? *Pathologe.* 2019 May;40(3):235-242. (IF: 0.55)
118. Liao L, Schneider KM, Galvez EJC, Frissen M, Marschall HU, Su H, Hatting M, Wahlström A, Haybaeck J, Puchas P, Mohs A, Peng J, Bergheim I, Nier A, Hennings J, Reißing J, Zimmermann HW, Longerich T, Strowig T, Liedtke C, Cubero FJ, Trautwein C. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. *Gut.* 2019 Aug;68(8):1477-1492. (IF: 17.94)
119. Lim PJ, Lindert U, Opitz L, Hausser I, Rohrbach M, Giunta C. Transcriptome Profiling of Primary Skin Fibroblasts Reveal Distinct Molecular Features Between PLOD1- and FKBP14-Kyphoscoliotic Ehlers-Danlos Syndrome. *Genes (Basel).* 2019 Jul 8;10(7). pii: E517. (IF: 3.33)
120. Linnebacher A, Mayer P, Marnet N, Bergmann F, Herpel E, Revia S, Yin L, Liu L, Hackert T, Giese T, Herr I, Gaida MM. Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer. *Cells.* 2019 Sep 18;8(9). pii: E1104. (IF: 5.66)
121. Löffler MW, Nussbaum B, Jäger G, Jurmeister PS, Budczies J, Pereira PL, Clasen S, Kowalewski DJ, Mühlenbruch L, Königsrainer I, Beckert S, Ladurner R, Wagner S, Bullinger F, Gross TH, Schroeder C, Sipos B, Königsrainer A, Stevanović S, Denkert C, Rammensee HG, Gouttefangeas C, Haen SP. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. *Front Immunol.* 2019 Nov 19;10:2526. (IF: 4.72)
122. Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, Jank P, Furlanetto J, Klauschen F, Karn T, Pfarr N, von Minckwitz G, Möbs M, Jackisch C, Sers C, Schneeweiss A, Fasching PA, Schem C, Hummel M, van Mackelenbergh M, Nekljudova V, Untch M, Denkert C. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. *Clin Cancer Res.* 2019 Jul 1;25(13):3986-3995. (IF: 8.91)

123. Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β -catenin activation in liver tumours. *Gut*. 2019 Jul;68(7):1287-1296. (IF: 17.94)
124. Longerich T, Schirmacher P. Emerging Role of the Pathologist in Precision Medicine for HCC. *Dig Dis Sci*. 2019 Apr;64(4):928-933. (IF: 2.94)
125. Longuespée R, Ly A, Casadonte R, Schwamborn K, Kazdal D, Zgorzelski C, Bollwein C, Kriegsmann K, Weichert W, Kriegsmann J, Schirmacher P, Fresnais M*, Oliveira C*, Kriegsmann M*. Identification of MALDI Imaging Proteolytic Peptides Using LC-MS/MS-Based Biomarker Discovery Data: A Proof of Concept. *Proteomics Clin Appl*. 2019 Jan;13(1):e1800158. (IF: 2.32)
126. Longuespée R, Kriegsmann K, Cremer M, Zgorzelski C, Casadonte R, Kazdal D, Kriegsmann J, Weichert W, Schwamborn K, Fresnais M, Schirmacher P, Kriegsmann M. In MALDI-Mass Spectrometry Imaging on Formalin-Fixed Paraffin-Embedded Tissue Specimen Section Thickness Significantly Influences m/z Peak Intensity. *Proteomics Clin Appl*. 2019 Jan;13(1):e1800074. (IF: 2.32)
127. Longuespée R, Casadonte R, Schwamborn K, Kriegsmann M. Proteomics in Pathology: The Special Issue. *Proteomics Clin Appl*. 2019 Jan;13(1):e1800167. (IF: 2.32)
128. Loosen SH, Tacke F, Püthe N, Binneboesel M, Wiltberger G, Alizai PH, Kather JN, Paffenholz P, Ritz T, Koch A, Bergmann F, Trautwein C, Longerich T, Roderburg C, Neumann UP, Luedde T. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. *Carcinogenesis*. 2019 Aug 22;40(8):947-955. (IF: 5.07)
129. Lozanovski VJ, Kerr LT, Khajeh E, Ghamarnejad O, Pfeiffenberger J, Hoffmann K, Chang DH, Mieth M, Longerich T, Strobel O, Weiss KH, Büchler MW, Mehrabi A. Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma. *J Clin Med*. 2019 Oct 15;8(10). pii: E1692. (IF: 2.05)
130. Ly A, Longuespée R, Casadonte R, Wandernoth P, Schwamborn K, Bollwein C, Marsching C, Kriegsmann K, Hopf C, Weichert W, Kriegsmann J, Schirmacher P, Kriegsmann M, Deininger SO. Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples. *Proteomics Clin Appl*. 2019 Jan;13(1):e1800029. (IF: (2.32)
131. Majenka P, Hoffmann M, Rötzer I, Dimitrakopoulou-Strauss A, Koschny R, Longerich T, Enk A, Hassel JC. Diet-dependent toxicity of ipilimumab in metastatic melanoma. *Eur J Cancer*. 2019 Jan;106:220-224. (IF: 6.68)
132. Mayer P, Grözinger M, Mokry T, Schemmer P, Waldburger N, Kauczor HU, Klaus M, Sommer CM. Semi-automated computed tomography Volumetry can predict hemihepatectomy specimens' volumes in patients with hepatic malignancy. *BMC Med Imaging*. 2019 Feb 26;19(1):20. (IF: 1.62)
133. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, Odunsi K, Steed H, Herpel E, Anglesio MS, Zhang B, Lambie N, Swerdlow AJ, Lubiński J, Vierkant RA, Goode EL, Menon U, Toloczko-Grabarek A, Oszurek O, Bilic S, Talhouk A, García-Closas M, Wang Q, Tan A, Farrell R, Kennedy CJ, Jimenez-Linan M, Sundfeldt K, Etter JL, Menkiszak J, Goodman MT, Klonowski P, Leung Y, Winham SJ, Moysich KB, Behrens S, Kluz T, Edwards RP, Gronwald J, Modugno F, Hernandez BY, Chow C, Kelemen LE, Keeney GL, Carney ME, Natanzon Y, Robertson G, Sharma R, Gayther SA, Alsop J, Luk H, Karpinskyj C, Campbell I, Sinn P, Gentry-Maharaj A, Coulson P, Chang-Claude J, Shah M, Widschwendter M, Tang K,

- Schoemaker MJ, Koziak JM, Cook LS, Brenton JD, Daley F, Kristjansdottir B, Mateoiu C, Larson MC, Harnett PR, Jung A, deFazio A, Gorringer KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Köbel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Mod Pathol.* 2019 Dec;32(12):1834-1846. (IF: 6.36)
134. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. *J Clin Oncol.* 2019 Nov 20;37(33):3142-3151. (IF: 28.25)
135. Mock A, Heilig CE, Kreutzfeldt S, Huebschmann D, Heining C, Schröck E, Brors B, Stenzinger A, Jäger D, Schlenk R, Glimm H, Fröhling S, Horak P; DTK MASTER Network. Community-driven development of a modified progression-free survival ratio for precision oncology. *ESMO Open.* 2019 Nov 13;4(6):e000583. (IF: unkn.)
136. Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP 4th, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, de Stanchina E, Zender L, Tong DR, D'Alessandro A, Lowe SW, Prives C. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. *Cell.* 2019 Jan 24;176(3):564-580.e19. (IF: 31.398)
137. Moratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, Hess J, Horn D. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. *Head Neck.* 2019 Aug;41(8):2484-2491. (IF: 2.44)
138. Mühlenberg T, Ketzer J, Heinrich MC, Grunewald S, Marino-Enriquez A, Trautmann M, Hartmann W, Wardelmann E, Treckmann J, Worm K, Bertram S, Herold T, Schildhaus HU, Glimm H, Stenzinger A, Brors B, Horak P, Hohenberger P, Fröhling S, Fletcher JA, Bauer S. KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy. *Mol Cancer Ther.* 2019 Nov;18(11):1985-1996. (IF: 4.86)
139. Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. *Lung Cancer.* 2019 Apr;130:194-200. (IF: 4.60)
140. Nagy Á, Ósz Á, Budczies J, Krizsán S, Szombath G, Demeter J, Bödör C, Györffy B. Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival. *J Adv Res.* 2019 Jun 11;20:105-116. (IF: 5.05)
141. Neumeyer V, Grandl M, Dietl A, Brutau-Abia A, Allgäuer M, Kalali B, Zhang Y, Pan KF, Steiger K, Vieth M, Anton M, Mejías-Luque R, Gerhard M. Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells. *Carcinogenesis.* 2019 Jun 10;40(4):551-559. (IF: 4.00)
142. Neumeyer S, Popanda O, Butterbach K, Edelmann D, Bläker H, Toth C, Roth W, Herpel E, Jäkel C, Schmezer P, Benner A, Burwinkel B, Hoffmeister M, Brenner H, Chang-Claude J. DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women. *Epigenomics.* 2019 Dec;11(16):1765-1778. (IF: 4.40)
143. Neumeyer S, Popanda O, Edelmann D, Butterbach K, Toth C, Roth W, Bläker H, Jiang R, Herpel E, Jäkel C, Schmezer P, Jansen L, Alwers E, Benner A, Burwinkel B, Hoffmeister M, Brenner

- H, Chang-Claude J. Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer. *Epigenetics*. 2019 May;14(5):477-493. (IF: 4.17)
144. Nickkholgh A, Ghamarnejad O, Khajeh E, Tinoush P, Bruckner T, Kulu Y, Mieth M, Goepfert B, Roessler S, Weiss KH, Hoffmann K, Büchler MW, Mehrabi A. Outcome after liver resection for primary and recurrent intrahepatic cholangiocarcinoma. *BJs Open*. 2019 Sep 10;3(6):793-801. (IF: unkn.)
145. Obazee O, Archibugi L, Andriulli A, Soucek P, Małecká-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel O, Kaiser J, Pezilli R, Federici F, Mohelnikova-Duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Paziienza V, Dervenis C, Sperti C, Mambriani A, Hackert T, Kaaks R, Basso D, Talar-Wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskis J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-Jazdzewska E, Canzian F. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. *Int J Cancer*. 2019 Aug 1;145(3):686-693. (IF: 4.98)
146. Omlor GW, Lange J, Streit M, Gantz S, Merle C, Germann T, Mechtersheimer G, Fellenberg J, Lehner B. Retrospective analysis of 51 intralesionally treated cases with progressed giant cell tumor of the bone: local adjuvant use of hydrogen peroxide reduces the risk for tumor recurrence. *World J Surg Oncol*. 2019 Apr 23;17(1):73. (IF: 1.97)
147. Omlor GW, Lohnherr V, Lange J, Gantz S, Mechtersheimer G, Merle C, Raiss P, Fellenberg J, Lehner B. Outcome of conservative and surgical treatment of enchondromas and atypical cartilaginous tumors of the long bones: retrospective analysis of 228 patients. *BMC Musculoskelet Disord*. 2019 Mar 28;20(1):134. (IF: 2.00)
148. Peters S, Dafni U, Boyer M, De Ruyscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). *Ann Oncol*. 2019 Feb;30(2):161-165. (IF: 14.20)
149. Petersen B, Busch CJ, Schleifer G, Schaack D, Lasitschka F, Bloch KD, Bloch DB, Ichinose F. Arginase impairs hypoxic pulmonary vasoconstriction in murine endotoxemia. *Respir Res*. 2019 Jun 3;20(1):109. (IF: 3.83)
150. Pfarr N, Allgäuer M, Steiger K, Weichert W, Schirmacher P, Noske A, Stenzinger A. Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. *Pathology*. 2019 Jun;51(4):362-368. (IF: 3.16)
151. Poth T, Schirmacher P, Lasitschka F. Center for Model System and Comparative Pathology (CMCP) – Erfahrungen in der Etablierung einer neuen Plattform zur Verknüpfung von human- und veterinärpathologischer Expertise. *Tierärztl Prax Ausg K*. 2019; 47(03): 211. (IF: unkn.)
152. Pottier C, Kriegsmann M, Alberts D, Smargiasso N, Baiwir D, Mazzucchelli G, Herfs M, Fresnais M, Casadonte R, Delvenne P, De Pauw E, Longuespée R. Microproteomic Profiling of High-Grade Squamous Intraepithelial Lesion of the Cervix: Insight into Biological Mechanisms of Dysplasia and New Potential Diagnostic Markers. *Proteomics Clin Appl*. 2019 Jan;13(1):e1800052. (IF: 2.32)

153. Radspieler MM, Schindeldecker M, Stenzel P, Försch S, Tagscherer KE, Herpel E, Hohenfellner M, Hatiboglu G, Roth W, Macher-Goeppinger S. Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma. *Oncol Lett.* 2019 Sep;18(3):2654-2660. (IF: 1.87)
154. Radtke JP, Giganti F, Wiesenfarth M, Stabile A, Marenco J, Orczyk C, Kasivisvanathan V, Nyarangi-Dix JN, Schütz V, Dieffenbacher S, Görtz M, Stenzinger A, Roth W, Freeman A, Punwani S, Bonekamp D, Schlemmer HP, Hohenfellner M, Emberton M, Moore CM. Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. *PLoS One.* 2019 Aug 26;14(8):e0221350. (IF: 2.77)
155. Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A, Sievers P, Huang K, Casalini MB, Fernández-Klett F, Suwala A, Weller M, Gramatzki D, Felsberg J, Reifenberger G, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Buslei R, Deckert M, Mawrin C, Hewer E, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Korshunov A, Reuss DE, Sahm F, Jones DTW, Capper D, von Deimling A. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathol Commun.* 2019 Oct 28;7(1):163. (IF: 5.88)
156. Richtmann S, Wilkens D, Warth A, Lasitschka F, Winter H, Christopoulos P, Herth FJF, Muley T, Meister M, Schneider MA. FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC. *Cancers (Basel).* 2019 May 11;11(5). pii: E652. (IF: 6.162)
157. Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. *Cancer.* 2019 Oct 15;125(20):3514-3525. (IF: 6.10)
158. Rong C, Muller M, Flechtenmacher C, Holzinger D, Dyckhoff G, Bulut OC, Horn D, Plinkert P, Hess J, Affolter A. Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma. *Cancers (Basel).* 2019 Apr 25;11(4). pii: E584. (IF: 6.16)
159. Rosenbaum M, Gewies A, Pechloff K, Heuser C, Engleitner T, Gehring T, Hartjes L, Krebs S, Krappmann D, Kriegsmann M, Weichert W, Rad R, Kurts C, Ruland J. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. *Nat Commun.* 2019 May 28;10(1):2352. (IF: 11.88)
160. Rubens U, Hoyoux R, Vanosmael L, Ouras M, Tasset M, Hamilton C, Longuespée R, Marée R. Cytomine: Toward an Open and Collaborative Software Platform for Digital Pathology Bridged to Molecular Investigations. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800057. (IF: 2.32)
161. Rusu P, Shao C, Neuerburg A, Acikgöz AA, Wu Y, Zou P, Phapale P, Shankar TS, Döring K, Dettling S, Körkel-Qu H, Bekki G, Costa B, Guo T, Friesen O, Schlotter M, Heikenwalder M, Tschaharganeh DF, Bukau B, Kramer G, Angel P, Herold-Mende C, Radlwimmer B, Liu HK. GPD1 Specifically Marks Dormant Glioma Stem Cells with a Distinct Metabolic Profile. *Cell Stem Cell.* 2019 Aug 1;25(2):241-257.e8. (IF: 21.46)
162. Saborowski A, Wolff K, Spielberg S, Beer B, Hartleben B, Erlangga Z, Becker D, Dow LE, Marhenke S, Woller N, Unger K, Schirmacher P, Manns MP, Marquardt JU, Vogel A, Saborowski M. Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. *Hepatology Commun.* 2019 Feb 5;3(3):423-436. (IF: unkn.)

163. Safi S, Yamauchi Y, Stamova S, Rathinasamy A, Op den Winkel J, Jünger S, Bucur M, Umansky L, Warth A, Herpel E, Eichhorn M, Winter H, Hoffmann H, Beckhove P. Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer. *Oncoimmunology*. 2019 Oct 23;8(12):e1671762. (IF: 5.33)
164. Schäfigen B, Harcos A, Kommoss F, Golatta M, Heil J, Riedel F, Schütz F, Sinn P, Sohn C. Axilläre Lymphknotenmetastasen eines okkulten hormonrezeptornegativen Mammakarzinoms bei kontralateralem hormonrezeptorpositivem Zweitkarzinom. *Senologie - Zeitschrift für Mammadiagnostik und -therapie* 2018. 2019; 16(04): 278–80. (IF: unkn.)
165. Scheil-Bertram S, Mechttersheimer G, Wardelmann E. Sitzungsbericht der AG Knochen-, Gelenk- und Weichgewebspathologie: DGP-Tagung am 13. Juni 2019, Frankfurt. *Pathologe*. 2019 Dec;40(Suppl 3):388-391. (IF: 0.55)
166. Schelb P, Kohl S, Radtke JP, Wiesenfarth M, Kickingereder P, Bickelhaupt S, Kuder TA, Stenzinger A, Hohenfellner M, Schlemmer HP, Maier-Hein KH, Bonekamp D. Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. *Radiology*. 2019 Dec;293(3):607-617. (IF: 7.608)
167. Schimmack S, Yang Y, Felix K, Herbst M, Li Y, Schenk M, Bergmann F, Hackert T, Strobel O. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. *Endocr Connect*. 2019 Jun 1; 8(7):1007-1019. (IF: 2.47)
168. Schirmacher P. Die Deutsche Gesellschaft für Pathologie – Ein Blick zurück nach vorne Festvortrag anlässlich der 103. Jahrestagung der DGP, Frankfurt am Main, 13.06.2019. *Pathologe*. 2019 Dec;40(Suppl 3):223-227. (IF: 0.55)
169. Schleicher C, Kreipe HH, Schemmer P, Strassburg CP, Fischer-Fröhlich CL, Rahmel A, Flechtenmacher C. Histologische Diagnostik bei Spenderlebern. Gemeinsame Empfehlungen von DGP, DTG und DSO. *Chirurg*. 2019 Nov;90(11):899-904. (IF: 0.67)
170. Schmitt K, Molfenter B, Laureano NK, Tawk B, Bieg M, Hostench XP, Weichenhan D, Ullrich ND, Shang V, Richter D, Stögbauer F, Schroeder L, de Bem Prunes B, Visioli F, Rados PV, Jou A, Plath M, Federspil PA, Thierauf J, Döscher J, Weissinger SE, Hoffmann TK, Wagner S, Wittekindt C, Ishaque N, Eils R, Klussmann JP, Holzinger D, Plass C, Abdollahi A, Freier K, Weichert W, Zaoui K, Hess J. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. *Int J Cancer*. 2019 Dec 15;145(12):3299-3310. (IF: 4.98)
171. Schmitteckert S, Mederer T, Röth R, Günther P, Holland-Cunz S, Metzger M, Samstag Y, Schröder-Braunstein J, Wabnitz G, Kurzhals S, Scheuerer J, Beretta CA, Lasitschka F, Rappold GA, Romero P, Niesler B. Postnatal human enteric neurospheres show a remarkable molecular complexity. *Neurogastroenterol Motil*. 2019 Oct;31(10):e13674. (IF: 3.80)
172. Schmöhl F, Peters V, Schmitt CP, Poschet G, Büttner M, Li X, Weigand T, Poth T, Volk N, Morgenstern J, Fleming T, Nawroth PP, Kroll J. CNDP1 knockout in zebrafish alters the amino acid metabolism, restrains weight gain, but does not protect from diabetic complications. *Cell Mol Life Sci*. 2019 Nov;76(22):4551-4568. (IF: 7.01)
173. Schübel R, Sookthai D, Greimel J, Johnson TS, Grafetstätter ME, Kirsten R, Kratz M, Ulrich CM, Kaaks R, Kühn T. Key Genes of Lipid Metabolism and WNT-Signaling Are Downregulated in Subcutaneous Adipose Tissue with Moderate Weight Loss. *Nutrients*. 2019 Mar 16;11(3). pii: E639. (IF: 4.17)
174. Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells

- and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. *Virchows Arch.* 2019 Nov;475(5):599-608. (IF: 2.87)
175. Scott DA, Casadonte R, Cardinali B, Spruill L, Mehta AS, Carli F, Simone N, Kriegsmann M, Del Mastro L, Kriegsmann J, Drake RR. Increases in Tumor N-Glycan Polylectosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. *Proteomics Clin Appl.* 2019 Jan;13(1):e1800014. (IF: 2.32)
176. Speer C, Kälble F, Nusschag C, Pego da Silva L, Schaier M, Becker LE, Klein K, Sommerer C, Beimler J, Leo A, Waldherr R, Mehrabi A, Süsal C, Zeier M, Morath C. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption - a retrospective study. *Transpl Int.* 2019 Dec;32(12):1286-1296. (IF: 3.53)
177. Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Schuetz F, Sohn C, Bohlmann MK, Sütterlin M, Schneeweiss A, Wallwiener M. Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. *Cancers (Basel).* 2019 Mar 11;11(3). pii: E342. (IF: 6.16)
178. Stenzinger A, Allen JD, Maas J, Stewart MD, Merino DM, Wempe MM, Dietel M. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. *Genes Chromosomes Cancer.* 2019 Aug;58(8):578-588. (IF: 2.94)
179. Stichel D, Schrimpf D, Casalini B, Meyer J, Wefers AK, Sievers P, Korshunov A, Koelsche C, Reuss DE, Reinhardt A, Ebrahimi A, Fernández-Klett F, Kessler T, Sturm D, Ecker J, Milde T, Herold-Mende C, Witt O, Pfister SM, Wick W, Jones DTW, von Deimling A, Sahm F. Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. *Acta Neuropathol.* 2019 Nov;138(5):827-835. (IF: 18.17)
180. Straub BK, Witzel HR, Pawella LM, Renner M, Eiteneuer E, Hashani M, Schirmacher P, Roth W, Mechttersheimer G. Perilipin 1 Expression Differentiates Liposarcoma from Other Types of Soft Tissue Sarcoma. *Am J Pathol.* 2019 Aug;189(8):1547-1558. (IF: 3.76)
181. Streubel A, Stenzinger A, Stephan-Falkenau S, Kollmeier J, Misch D, Blum TG, Bauer T, Landt O, Am Ende A, Schirmacher P, Mairinger T, Endris V. Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. *Oncotarget.* 2019 Oct 1;10(55):5690-5702. (IF: 5.17)
182. Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N. CCR5 status and metastatic progression in colorectal cancer. *Oncoimmunology.* 2019 Jul 13;8(9):e1626193. (IF: 5.33)
183. Süßmuth K, Metze D, Ullrich N, Hausser I, Fischer J, Steinbrink K, Traupe H, Oji V. Neue Therapieansätze für entzündliche und bullöse Formen kongenitaler Ichthyosen: erste klinische Erfahrungen. *J Dtsch Dermatol Ges.* 2019 May;17 Suppl 2:12-15. (IF: 3.92)
184. Sundaram B, Behnke K, Belancic A, Al-Salihi MA, Thabet Y, Polz R, Pellegrino R, Zhuang Y, Shinde PV, Xu HC, Vasilevska J, Longerich T, Herebian D, Mayatepek E, Bock HH, May P, Kordes C, Aghaeepour N, Mak TW, Keitel V, Häussinger D, Scheller J, Pandya AA, Lang KS, Lang PA. iRhom2 inhibits bile duct obstruction-induced liver fibrosis. *Sci Signal.* 2019 Oct 29;12(605). pii: eaax1194. (IF: 6.48)

185. Thielmann CM, Costa da Silva M, Muley T, Meister M, Herpel E, Muckenthaler MU. Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma. *Sci Rep.* 2019 Aug 5;9(1):11326. (IF: 4.01)
186. Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. *Breast Care (Basel).* 2019 Aug;14(4):247-255. (IF: 2.09)
187. Thoeni C, Waldherr R, Scheuerer J, Schmitteckert S, Roeth R, Niesler B, Cutz E, Flechtenmacher C, Goeppert B, Schirmacher P, Lasitschka F. Expression Analysis of ATP-Binding Cassette Transporters ABCB11 and ABCB4 in Primary Sclerosing Cholangitis and Variety of Pediatric and Adult Cholestatic and Noncholestatic Liver Diseases. *Can J Gastroenterol Hepatol.* 2019 Dec 10;2019:1085717. (IF: 1.72)
188. Thoeni C, Holzer K, Leichsenring J, Porcel C, Straub BK, Sinn HP, Elsaesser M, Volckmar AL, Schirmacher P, Waldherr R, Lasitschka F. Renal Tubular Dysgenesis in a Case of Fetus Acardius Amorphus. *Case Rep Pathol.* 2019 Nov 12;2019:5416936. (IF: unkn.)
189. Toberer F, Christopoulos P, Lasitschka F, Enk A, Haenssle HA, Cerroni L. Double-positive CD8/CD4 primary cutaneous acral T-cell lymphoma. *J Cutan Pathol.* 2019 Mar;46(3):231-233. (IF: 1.52)
190. Tomassen T, Koelsche C, de Leng WWJ, Kommos FKF, Voijs CMA, Peeters T, van Noesel MM, Creytens D, van Gorp JM, Petersen I, Vokuhl C, von Deimling A, Mentzel T, Flucke U. Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. *Ann Diagn Pathol.* 2019 Aug;41:102-105. (IF: 1.61)
191. Treue D, Bockmayr M, Stenzinger A, Heim D, Hester S, Klauschen F. Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR-mutated lung cancer. *Int J Cancer.* 2019 Feb 1;144(3):545-557. (IF: 4.98)
192. Uhrig M, Mueller J, Longerich T, Straub BK, Buschle LR, Schlemmer HP, Mueller S, Ziener CH. Susceptibility based multiparametric quantification of liver disease: Non-invasive evaluation of steatosis and iron overload. *Magn Reson Imaging.* 2019 Nov;63:114-122. (IF: 3.73)
193. Varga Z, Sinn P, Seidman AD. Author's reply to: Comparing the performance of gene expression assays in breast cancer. *Int J Cancer.* 2019 Aug 15;145(4):1163-1164. (IF: 4.98)
194. Varga Z, Sinn P, Seidman AD. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. *Int J Cancer.* 2019 Aug 15;145(4):882-893. (IF: 4.98)
195. Viarisio D, Robitaille A, Müller-Decker K, Flechtenmacher C, Gissmann L, Tommasino M. Cancer susceptibility of beta HPV49 E6 and E7 transgenic mice to 4-nitroquinoline 1-oxide treatment correlates with mutational signatures of tobacco exposure. *Virology.* 2019 Dec;538:53-60. (IF: 2.66)
196. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2019 May 1;30(5):871-873. (IF: 14.20)

197. Vogt PH, Besikoglu B, Bettendorf M, Frank-Herrmann P, Zimmer J, Bender U, Knauer-Fischer S, Choukair D, Sinn P, Lau YC, Heidemann PH, Strowitzki T. Gonadoblastoma Y locus genes expressed in germ cells of individuals with dysgenetic gonads and a Y chromosome in their karyotypes include DDX3Y and TSPY. *Hum Reprod.* 2019 Apr 1;34(4):770-779. (IF: 5.51)
198. Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goepfert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. *Int J Cancer.* 2019 Aug 1;145(3):649-661. (IF: 4.98)
199. Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A. Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. *Genes Chromosomes Cancer.* 2019 Jan;58(1):3-11. (IF: 2.94)
200. Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M. Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease. *Respiration.* 2019;97(4):348-354. (IF: 2.93)
201. Wagner NB, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Schadendorf D, Garbe C, Umansky V, Utikal J, Gebhardt C. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies. *J Immunother Cancer.* 2019 Dec 5;7(1):343. (IF: 8.73)
202. Wagner P, Kommos FKF, Kommos S, Hartkopf AD, Pasternak I, Oberlechner E, Greif K, Wallwiener M, Neis F, Abele H, Krämer B, Reisenauer C, Staebler A, Wallwiener D, Brucker SY, Taran FA. Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease. *Gynecol Oncol.* 2019 Apr;153(1):49-54. (IF: 4.39)
203. Waly AA, El-Ekiaby N, Assal RA, Abdelrahman MM, Hosny KA, El Tayebi HM, Esmat G, Breuhahn K, Abdelaziz AI. Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. *Front Physiol.* 2019 Jan 24;9:1918. (IF: 3.20)
204. Wehling C, Hornuss D, Schneider P, Springfield C, Hoffmann K, Chang DH, Naumann P, Mieth M, Longerich T, Kratochwil C, Mehrabi A, Gauss A, Weiss KH, Pfeiffenberger J. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma. *J Cancer Res Clin Oncol.* 2019 Nov;145(11):2761-2769. (IF: 3.33)
205. Wei T, Weiler SME, Tóth M, Sticht C, Lutz T, Thomann S, De La Torre C, Straub B, Merker S, Ruppert T, Marquardt J, Singer S, Gretz N, Schirmacher P, Breuhahn K. YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. *Oncogene.* 2019 Jul;38(27):5541-5550. (IF: 6.63).
206. Weigel C, Chaisaingmongkol J, Assenov Y, Kuhmann C, Winkler V, Santi I, Bogatyrova O, Kaucher S, Bermejo JL, Leung SY, Chan TL, Lasitschka F, Bohrer MH, Marx A, Haußen RH, Herold-Mende C, Dyckhoff G, Boukamp P, Delank KW, Hörmann K, Lippert BM, Baier G, Dietz A, Oakes CC, Plass C, Becher H, Schmezer P, Ramroth H, Popanda O. DNA methylation at an enhancer of

- the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer. *Clin Epigenetics*. 2019 May 3;11(1):67. (IF: 5.50)
207. Wing PA, Davenne T, Wettengel J, Lai AG, Zhuang X, Chakraborty A, D'Arienzo V, Kramer C, Ko C, Harris JM, Schreiner S, Higgs M, Roessler S, Parish JL, Protzer U, Balfe P, Rehwinkel J, McKeating JA. A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. *Life Sci Alliance*. 2019 Mar 27;2(2). pii: e201900355. (IF: 3.45)
208. Xia Z, Cochrane DR, Tessier-Coutier B, Leung S, Karnezis AN, Cheng AS, Farnell DA, Magrill J, Schmidt D, Kommos S, Kommos FKF, Kommos F, McAlpine JN, Gilks CB, Koebel M, Rabban JT, Huntsman DG. Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. *Hum Pathol*. 2019 Oct;92:39-47. (IF: 2.74)
209. Xie L, Xia L, Klaiber U, Sachsenmaier M, Hinz U, **Bergmann F**, Strobel O, Büchler MW, Neoptolemos JP, Fortunato F, Hackert T. Effects of neoadjuvant FOLFIRONOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma. *Oncotarget*. 2019 Dec 31;10(68):7276-7287. (IF: 5.17)
210. Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, Levins C, Kong T, Zhu X, Morin G, Skerritt L, Herpel E, Venneti S, Martinez D, Judkins AR, Jung S, Camilleri-Broet S, Gonzalez AV, Guiot MC, Lockwood WW, Spicer JD, Agaimy A, Pastor WA, Dostie J, Rak J, Foulkes WD, Huang S. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. *Nat Commun*. 2019 Feb 4;10(1):557. (IF: 11.88)
211. Zhou X, Wuchter P, Egerer G, Kriegsmann M, Mataityte A, Koelsche C, Witzens-Harig M, Kriegsmann K. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma. *Eur J Haematol*. 2019 Oct;103(4):410-416. (IF: 2.22)
212. Zhou C, Moustafa MR, Cao L, Kriegsmann M, Winter M, Schwager C, Jones B, Wang S, Bäuerle T, Zhou PK, Schnölzer M, Weichert W, Debus J, Abdollahi A. Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation. *Int J Cancer*. 2019 Jun 15;144(12):3160-3173. (IF: 4.98)

Book chapters

Dienes HP, Schirmacher P. (2019). Liver Pathology of Wilson Disease. In: Wilson Disease. 1st Edition. Weiss KH, Schilsky M (eds.), Academic Press, pp. 139-144. ISBN: 9780128110775.

Odze RD, Cree IA, Klimstra DS, Nagtegaal ID, Paradis V, Ruge M, Schirmacher, P. (2019). Introduction to tumours of the digestive system. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp. 14-15. ISBN: 978-92-832-4499-8.

Schirmacher P, Fukayama M, Paradis V, Park YN. (2019). Tumours of the liver and intrahepatic bile ducts: Introduction. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, p. 220. ISBN: 978-92-832-4499-8.

Sempoux C, Kadar S, Kondo F, Schirmacher P. (2019). Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp.260-262. ISBN: 978-92-832-4499-8.

Schirmacher, P. (2019). Digestive System Metastases. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp. 506-509. ISBN: 978-92-832-4499-8.

Winkler E et al. (2019). Stellungnahme zur Herausgabe genomischer Rohdaten an Patient_Innen und Studienteilnehmende. Marsilius Kolleg.

Editor:

Paradis V, Fukayama M, Park YN, Schirmacher, P. (2019). Chapter 8: Tumours of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp. 215-264. ISBN: 978-92-832-4499-8.

Klimstra DS, Lam AK, Paradis V, Schirmacher P. (2019). Chapter 9: Tumours of the gallbladder and extrahepatic bile ducts. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp. 265-294. ISBN: 978-92-832-4499-8.

Paradis V, Schirmacher P, Singh R. (2019). Chapter 13: Other tumours of the digestive system. In: WHO Classification of Tumours. Digestive System Tumours. Fifth Edition. WHO Classification of Tumours Editorial Board (eds.), Vol. 1, WHO Press, Switzerland, pp. 499-509. ISBN: 978-92-832-4499-8.